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Hepatitis C virus (HCV) entry is dependent on core-
ceptor complex formation between the tetraspanin
superfamily member CD81 and the tight junction
protein claudin-1 (CLDN1) on the host cell mem-
brane. The receptor tyrosine kinase EGFR acts as a
cofactor for HCV entry by promoting CD81-CLDN1
complex formation via unknown mechanisms. We
identify the GTPase HRas, activated downstream of
EGFR signaling, as a key host signal transducer for
EGFR-mediated HCV entry. Proteomic analysis re-
vealed that HRas associates with tetraspanin CD81,
CLDN1, and the previously unrecognized HCV entry
cofactors integrin b1 and Ras-related protein
Rap2B in hepatocyte membranes. HRas signaling is
required for lateral membrane diffusion of CD81,
which enables tetraspanin receptor complex
assembly. HRas was also found to be relevant for
entry of other viruses, including influenza. Our data
demonstrate that viruses exploit HRas signaling for
cellular entry by compartmentalization of entry
factors and receptor trafficking.
INTRODUCTION
Viral entry into target cells requires the coordinated interaction
of viral and host factors. Cellular kinases play a role in virus302 Cell Host & Microbe 13, 302–313, March 13, 2013 ª2013 Elsevieuptake (Chakraborty et al., 2012; Mercer and Helenius, 2008;
Pelkmans et al., 2005), but the underlying molecular mecha-
nisms and signaling pathways are only poorly understood.
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and
hepatocellular carcinoma (HCC) (El-Serag, 2012). Major chal-
lenges include the absence of a preventive vaccine and resis-
tance to antiviral treatment in a large fraction of patients (Zeisel
et al., 2011). HCV is an enveloped, positive-sense single-
stranded RNA virus of the Flaviviridae family (Murray and Rice,
2011). Virus entry into hepatocytes is a multistep process that
is regulated by receptor tyrosine kinases (RTKs) (Lupberger
et al., 2011). Host cell factors for the initiation of infection include
heparan sulfate (Barth et al., 2006), CD81 (Pileri et al., 1998),
scavenger receptor type B class I (SR-BI) (Scarselli et al.,
2002), claudin-1 (CLDN1) (Evans et al., 2007), occludin (OCLN)
(Liu et al., 2009; Ploss et al., 2009), and Niemann-Pick C1-like
1 cholesterol absorption receptor (NPC1L1) (Sainz et al., 2012).
Virus entry is a promising target for antiviral therapy since host
cell receptors exhibit a high genetic barrier to viral resistance
(Zeisel et al., 2011).
CD81 belongs to the tetraspanin superfamily of integral trans-
membrane proteins that have been implicated in a variety of
physiological and pathological processes and play a role in path-
ogen infection (Ko¨nig et al., 2010; Krementsov et al., 2010; Silvie
et al., 2003). Tetraspanins are highly organized in microdomains
displaying specific and direct interactions with other tetraspa-
nins and molecular partners. Tetraspanins are implicated in
membrane protein trafficking, partitioning, and clustering in tet-
raspanin-enriched microdomains (TEMs) that regulate signaling
pathways by membrane compartmentalization (Berditchevski
and Odintsova, 2007; Chambrion and Le Naour, 2010).r Inc.
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HRas and Tetraspanin-Mediated HCV EntryCD81 has a dynamic nature in HCV entry and its lateral diffu-
sion regulates HCV infection (Harris et al., 2012). The physical
interaction of CD81 with CLDN1 in a coreceptor complex is
a prerequisite and essential step for HCV entry (Harris et al.,
2010; Krieger et al., 2010). We demonstrated that RTKs, like
epidermal growth factor receptor (EGFR), act as cofactors for
HCV entry by promoting the formation of the CD81-CLDN1 cor-
eceptor complexes, but the molecular mechanism is unknown
(Lupberger et al., 2011). Unlike CD81, EGFR does not directly
bind HCV E2, and, furthermore, EGFR activity directly correlates
with HCV entry (Lupberger et al., 2011). Taken together, this
highlights an essential role for RTK signaling in regulating the
HCV entry process. Since EGFR supports the uptake of different
viruses (Karlas et al., 2010; Lupberger et al., 2011; Pelkmans
et al., 2005), it is likely that EGFR signaling plays a role in the entry
of other virus families. To uncover the molecular mechanism
underlying EGFR-regulated virus entry, we investigated the
signaling pathway(s) and cellular transducers mediating HCV
entry and investigated their impact on host receptor association
and motility.
RESULTS
EGF Predominantly Activates Ras/MAPK Signaling in
HCV Permissive Hepatic Cells
To identify the host signaling pathway of RTK-mediated HCV
entry, we first studied EGFR signaling in Huh7.5.1 cells—
a state-of-the-art permissive cell line for HCV infection, primary
human hepatocytes (PHHs), and patient-derived liver biopsies.
EGFR activation leads to phosphorylation of tyrosine residues
in the intracellular domain that recruit signaling molecules to
the plasma membrane that prime subsequent activation of
events (Morandell et al., 2008), including mitogen-activated
protein kinase (MAPK), phosphoinositide-3 kinase (PI3K), and
v-Akt murine thymoma viral oncogene homolog (AKT) pathway
activation (Figure 1A). Analysis of signal transduction in
Huh7.5.1 cells, PHHs, and liver tissue (liver biopsies 987 and
990) with phosphokinase (Figures 1B and 1C and Figure S1A
available online) and phospho-RTK arrays (Figures 1C and
S1B) demonstrates that EGFR and the Ras/MAPK pathway are
predominantly activated after EGF stimulation in human hepato-
cytes in vitro and in vivo. In contrast, activation of signaling path-
ways described in other cell lines and tissues (PI3K/AKT, PLC/
PKC, p38/JNK, STAT3/5, Cbl, c-Src/ABL, and FAK) was less
relevant in the liver-derived cells, PHHs, or liver tissue (Figures
1B, 1C, and S1) as shown by phosphorylation arrays. To further
corroborate the relevance of the Ras/MAPK pathway as the
primary signal transducer of EGFR in the liver, we measured
the phosphorylation status of extracellular signal-regulated
kinases 1 and 2 (ERK1/ERK2) and AKT by dynamic phosphoflow
assay following EGFR stimulation (Firaguay and Nune`s, 2009)
(Figures S1C–S1F) in Huh7.5.1 and PHHs. EGF stimulation of
Huh7.5.1 cells and PHHs activates Ras/MAPK signaling, while
even prolonged incubation of the cells with EGF failed to activate
the PI3K/AKT pathway (Figures S1D–S1F). Similar results were
obtained by immunoblot of phosphoproteins in EGF-stimulated
Huh7.5.1 or PHH lysates (Figure S1G) and lysates from
patient-derived liver tissue (liver biopsies 956, 965, and 968)
that had been stimulated with EGF ex vivo (Figure 1D). We notedCell Hothat EGF activated ERK1/ERK2 at significantly lower doses in
Huh7.5.1 cells and PHHs (Figure S1G). In summary, these results
demonstrate that EGF predominantly activates the Ras/MAPK
pathway in hepatoma cells, PHHs, and liver tissue supporting
the key relevance of the Ras/MAPK pathway for EGFR-mediated
signaling in the liver.
EGFR Scaffolding Proteins Grb2 and Shc1 Are Relevant
for HCV Entry
To identify EGFR-mediated signals important for HCV entry, we
performed an unbiased small interfering RNA (siRNA) screen
targeting the expression of known EGFR adaptors and associ-
ated proteins (Table S1). Among the identified EGFR scaffolding
proteins with impact on HCV entry, we identified growth factor
receptor-bound protein 2 (Grb2) and Src homology 2 domain-
containing transforming protein 1 (Shc1): known activators of
Ras GTPases and MAPK pathway (Kolch, 2005) (Figure 1A).
Although STAT5b scored as a binding partner with potential
functional relevance (Table S1), we observed no evidence for
activation of the STAT5 signaling in EGF-treated PHHs or liver
tissue (Figures 1 and S1A), and a STAT5b inhibitor had no effect
on HCV entry as described below. Thus, we focused on the
functional relevance of Grb2 and Shc1 for HCV entry. Silencing
of Grb2 or Shc1 expression significantly (p < 0.01) decreased
HCV pseudoparticle (HCVpp) entry (Figure 2A) and cell-culture-
derived HCV (HCVcc) infection (Figure 2B) to similar levels as
EGFR silencing, while silencing Grb2-associated binding protein
1 (Gab1) that recruits PI3K (Figure 1A) had no effect on HCV
infection (Figures 2A and 2B). Specific Grb2, Shc1, and Gab1
gene silencing was validated by immunoblot (Figure 2C). In
contrast, silencing of Grb2 or Shc1 expression had no effect
on the entry of murine leukemia virus (MLV) pseudoparticles
(Figure 2D), suggesting that the observed inhibitory effect is
not related to the pseudoparticle system. Finally, we confirmed
the functional relevance of Grb2 and Shc1 in HCVpp infection
of polarized HepG2-CD81 cells (Figure 2E). HepG2 cells polarize
in vitro and develop bile-canaliculi-like spaces between adjacent
cells, thus allowing the study of virus entry in a model system
closely related to polarized hepatocytes in the infected liver
in vivo (Mee et al., 2009). Taken together, these data show
a role for EGFR scaffolding proteins Grb2 and Shc1 in HCV entry
and infection.
Inhibition of Ras and Upstream MAPK BRaf Decreases
HCV Entry
Since silencing of EGFR scaffolding proteins Grb2 and Shc1
inhibits HCV entry and these proteins activate Ras/MAPK
signaling, we investigated whether other members of the
MAPK pathway play a role in HCV entry. We thus used a panel
of well-characterized small-molecule inhibitors (Figure 1A) of
EGFR (erlotinib), rat sarcoma (Ras) (tipifarnib), Raf (sorafenib),
BRaf (inhibitor VI), Raf-1 (inhibitor I), mitogen-activated protein
kinase 1 and 2 (MEK1/MEK2) (U0126), and ERK1/ERK2
(Fr180204) and studied their effect(s) on HCV entry and infection
(Figures 3A–3F). We also ruled out a role of other major EGFR
signaling pathways including PI3K/AKT, PLC/PKC, p38/JNK,
STAT3/5, and FAK using well-described small-molecule inhibi-
tors (Figure 3G). The biological activity of all used inhibitors
was confirmed in functional assays in Huh7.5.1 (Figure S2).st & Microbe 13, 302–313, March 13, 2013 ª2013 Elsevier Inc. 303
Figure 1. EGFR Signaling Pathways in Human HCV-Permissive Liver Cells, Hepatocytes, and Patient-Derived Liver Tissue
(A) Scheme of the two main canonical EGFR signaling cascades: the MAPK and the PI3K/AKT pathways. Inhibitors targeting members of these pathways are
indicated.
(B and C) EGFR-transduced signals in human hepatocytes and liver tissue. (B) Detection of kinase phosphorylation in Huh7.5.1 and PHHs after EGF treatment
(1 mg/ml; 15 min) with a human phosphokinase array detecting specific phosphorylation of 46 phosphorylation sites on 32 cellular kinases, which are indicated in
Figure S1A. (C) Detection of RTK and kinase phosphorylation in liver tissue of patient biopsy 990 after EGF treatment (1 mg/ml; 15 min ex vivo) with a human
phospho-RTK array (detecting specific phosphorylation of 42 different RTKs as indicated in Figure S1B) and a human phosphokinase array.
(D) Analysis of the phosphorylated and total forms of ERK1/ERK2 and AKT with specific antibodies in three different liver biopsies (956, 965, and 968) after 15 min
EGF stimulation (1 mg/ml) ex vivo. Total protein (30 mg) was separated by SDS-PAGE and stained for total and phosphorylated forms of ERK and AKT by
immunoblot.
See also Figure S1 for more-detailed analyses of EGFR signaling.
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HRas and Tetraspanin-Mediated HCV EntryAll inhibitor concentrations were well tolerated in Huh7.5.1 and
PHHs, as shown by MTT assays applied for inhibitors that
inhibited HCV entry (Figures 3A and 3B). Since erlotinib and
tipifarnib resulted in a robust, donor-independent, and highly
significant (p < 0.0001) inhibition of HCVpp entry in hepatoma
cells and PHHs, we conclude that Ras is a predominant signal
transducer required for EGFR-mediated HCV entry. Inhibition
of Ras and upstream MAPK Raf, and to some extent MEK1/
MEK2, decreased HCVpp and HCVcc infection in Huh7.5.1 cells
and PHHs (Figures 3C–3E). Moreover, a different inhibition
profile of MLVpp infection of PHHs suggests that the effects
are not related to the lentiviral system (Figure 3F). Taken
together, our observations demonstrate that the closer the
inhibitor’s target is toward EGFR in the MAPK signaling cascade
(Figure 1A), the more efficiently HCV entry is inhibited. These
data suggest that only upstreammembers of theMAPK signaling304 Cell Host & Microbe 13, 302–313, March 13, 2013 ª2013 Elseviepathway, but not other canonical EGFR pathways, play a major
functional role in HCV entry.
HRas Is a Transducer of EGFR-Mediated HCV Entry
The classical Ras family comprises three isotypes: Harvey (H)-,
Kirsten (K)-, and neuroblastoma (N)-Ras (Boguski and McCor-
mick, 1993). Since Grb2, Shc1 and Raf play a role in EGFR-
mediated HCV entry (Figures 2 and 3), we investigated the
functional role of the Ras GTPase family in HCV entry using
RNA interference (RNAi). HRas, KRas, or NRas expression (Fig-
ure S3A) was silenced in Huh7.5.1 with two individual siRNAs per
target (Figures 4A–4C). The messenger RNA (mRNA) or protein
expression after silencing was studied for all Ras isoforms or
HRas, respectively (Figures 4A and 4B). Silencing of HRas
expression markedly and significantly (p < 0.0005) decreased
HCV entry into Huh7.5.1 cells to a comparable level as EGFRr Inc.
Figure 2. EGFR Adaptors Grb2 and Shc1 Are Relevant for HCV Entry
Silencing of EGFR adaptors Grb2 and Shc1 inhibits HCV entry. Huh7.5.1 (A–C) and polarized HepG2-CD81 (D and E) cells were transfected with individual siRNA
directed against Gab1, Grb2, or Shc1 and infected with HCVpp, MLVpp, or HCVcc.
(A, C, and E) Silencing of protein expression was confirmed by immunoblot with specific antibodies targeting Gab1, Grb2, Shc1, or actin (C). HCVpp entry was
assessed in Huh7.5.1 (A) and in polarized HepG2-CD81 (E) cells transfected with siRNA. siCTRL, CD81- and EGFR-specific siRNAs served as internal controls.
Data are expressed as percentage HCVpp entry relative to siCTRL-transfected cells (means ± SD from three independent experiments in triplicate, n = 9).
(B) HCVcc infection in Huh7.5.1 cells transfected with the same siRNAs. Data are expressed as percentage HCVcc infection relative to siCTRL-transfected cells
(means ± SD from three independent experiments in triplicate, n = 9).
(D) MLVpp entry in polarized HepG2-CD81 cells. Data are expressed as percentage MLVpp entry relative to siCTRL-transfected cells (means ± SD from three
independent experiments in triplicate, n = 9).
*p < 0.01. See also Table S1.
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HRas and Tetraspanin-Mediated HCV Entrysilencing (Figure 4C). In contrast, silencing KRas or NRas
expression had no detectable effect on HCV entry (Figure 4C).
Isoform specificity of HRas gene silencing was validated by
qRT-PCR (Figure S3B). Moreover, HRas silencing reduced
EGF-induced ERK1/ERK2 phosphorylation, supporting a role
of HRas in EGF-induced MAPK activation in hepatocytes
(Figure S3C). These results demonstrate a specific role for the
GTPase HRas in the HCV entry process.
Since EGFR mediates entry of viruses other than HCV, we
studied the role of HRas on the entry of lentiviral pseudoparticles
expressing glycoproteins from avian fowl plague virus influenza
A (H7/N1), measles virus, MLV, endogenous feline virus
RD114, and vesicular stomatitis virus (VSV) in Huh7.5.1 cells.
Silencing HRas expression had a significant (p < 0.0005) inhibi-
tory effect on the entry of influenza andmeasles pseudoparticles
(Figure 4D), suggesting that these viruses require similar sig-
naling pathways to enter hepatoma cells as HCV. Although we
previously demonstrated that EGFR silencing had no effect on
measles virus entry (Lupberger et al., 2011), HRas silencing
impacts measles virus entry, suggesting an EGFR-independent
role of HRas in this process.
To confirm the HRas dependency of EGFR-mediated HCV
entry, we performed inhibition/rescue experiments using the
EGFR inhibitor erlotinib and the patient-derived transdominant
active V12 mutant of HRas (Beause´jour et al., 2003). Huh7.5.1
or PHHs were transduced to express the HRas V12 mutant
and 72 hr later evaluated for their HCVpp permissivity in the
presence or absence of 10 mM erlotinib (Figures 4E and 4F).
Exogenous HRas expression in Huh7.5.1 and PHHs was
confirmed by HRas-specific immunoblot (Figure S3D). The
HRas V12 mutant increased HCVpp infection of Huh7.5.1 and
PHHs in the absence of erlotinib, demonstrating an involvement
of HRas in HCV entry (Figures 4E and 4F). Moreover, HRas V12Cell Homutant rescued the inhibitory effect of erlotinib on HCV entry,
confirming that HRas mediates EGFR-dependent HCV entry
(Figures 4E and 4F).
Next, we investigated whether HRas mediates EGFR-depen-
dent cell-cell transmission using a well-established cell-cell
transmission assay (Lupberger et al., 2011). Reduction of
(siHRas.6) or increase of (pHRas V12) HRas expression (Fig-
ures 4G and S3E–S3G) in target cells impaired significantly
(p < 0.0005) or enhanced cell-cell transmission compared to
control-transduced cells, respectively. Furthermore, the HRas
inhibitor tipifarnib blocked HCV cell-cell transmission (Figures
4G and S3G). These data highlight a previously unrecognized
role of HRas during viral spread.
HRas Associates with HCV Cell Entry Factors CD81
and CLDN1
EGFR promotes the association of CD81-CLDN1 coreceptor
complexes that are important for HCV entry (Lupberger et al.,
2011). To investigate whether EGFR signaling modulates
CD81-CLDN1 association, we analyzed whether TEMs contain
members of the EGFR signaling pathways using proteomic anal-
ysis of CD81 immunoprecipitates. HepG2 and HepG2-CD81
cells were differentially labeled with stable isotope labeling with
amino acids (SILAC) (Ong et al., 2002) and lysed with brij97
detergent that is reported to preserve tetraspanin interactions
(Le Naour et al., 2006), and HepG2 and HepG2-CD81 lysates
were pooled equally according to SILAC protocols (Ong et al.,
2002). From this pool, CD81 was pulled down with beads
coupled with CD81-specific IgG and coprecipitated protein
complexes analyzed by mass spectrometry. Among the CD81
coprecipitated proteins were several integrins (alpha1, alpha6,
and beta1) that are well-characterized TEM components. There-
fore, we defined the threshold of specificity >2 accordingly to thest & Microbe 13, 302–313, March 13, 2013 ª2013 Elsevier Inc. 305
Figure 3. Upstream MAPK Are Relevant for HCV Entry in Hepatoma Cells and Human Hepatocytes
Cell survival (A and B), HCVpp entry (C, E, andG), HCVcc infection (D), or MLVpp entry (F) in Huh7.5.1 cells (A, C, D, and G) or PHHs (B, E, F, and G) incubatedwith
small-molecule inhibitors (10 mM) targeting EGFR (erlotinib), Ras (tipifarnib), Raf (sorafenib,10 mM for pseudoparticles and 1 mM for HCVcc), BRaf (Raf inhibitor VI),
Raf-1 (Raf inhibitor I), MEK1/MEK2 (U0126), or ERK1/ERK2 (Fr180204) or the major EGFR pathways, including PI3K (wortmannin and LY294,002), STAT3
(Cpd188), STAT5 (573108), PKC (Go¨6976), PLC (U-73122), FAK (PF573288), p38 (SB203580), JNK (JNK inhibitor II), and Ras (tipifarnib). One hour after incubation
with inhibitors, HCVpp,MLVpp, or HCVccwas added to the cells in the presence of inhibitors. Cell viability was assessed byMTT assay. EGFR (erlotinib) serves as
internal control. Data are expressed as percentage HCVpp or MLVpp entry and HCVcc infection relative to solvent CTRL-treated cells (means ± SEM from four
independent experiments in triplicate, n = 12). *p < 0.0001. See also Figure S2.
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HRas and Tetraspanin-Mediated HCV Entryisotope ratio 13C/12C of coprecipitated integrins and accordingly
to SILAC standard procedures (Ong et al., 2002). Above this
threshold, we identified tetraspanin-associated proteins such
as membrane protease ADAM10, several tetraspanins (CD9,
CD81, CD151), and known specific interaction partners of
CD81, such as EWI-2 and CD9P-1/EWIF, validating this differen-
tial proteomic approach to identify CD81-associated proteins.
Interestingly, HCV entry factors CLDN1 and SR-BI but not
OCLN or NPC1L1 were identified as CD81 TEM components
corroborating a close cooperation of CD81, CLDN1, and SR-BI
during HCV entry (Krieger et al., 2010). These results were
confirmed in a second experiment using SILAC proteomics
with inverted isotope labeling (Table 1). Among the 169 compo-
nents identified in TEMs, we identified HRas as the only member
of the canonical EGFR signaling pathways associating with
CD81. A physical interaction of HRas with the tetraspanin core-
ceptor complex was further supported by a partial but robust
colocalization of CD81 with HRas at the plasma membrane of
Huh7 cells (Figure S4A) as calculated according to Pearson
(Rr = 0.25) and Manders (R = 0.659) coefficients and intensity
correlation quotient (ICQ = 0.129) (Bolte and Cordelie`res, 2006;306 Cell Host & Microbe 13, 302–313, March 13, 2013 ª2013 ElsevieBrown et al., 2010; Manders et al., 1992) (Figure S4). To further
study the relevance and robustness of the HRas-CD81 colocal-
ization, we transduced cells to express the HRas V12 mutant
(Figure S4B). The colocalization of HRas V12 with CD81 was
calculated (Image J software) and significantly (p < 0.005)
increased as demonstrated by the Pearson (Rr = 0.544 ±
0.047) and Manders (R = 0.825 ± 0.056) coefficients and ICQ
(0.387 ± 0.067) as compared to empty vector (Rr = 0.278 ±
0.054; R = 0.820 ± 0.05; ICQ = 0.175 ± 0.022) (Figures S4C
and S4D). The distribution of HRas at the plasma membrane
was observed as intense punctuated spots and correlated with
high CD81 content. Taken together, these data suggest that
active HRas physically associates with CD81.
Functional Network Analyses of CD81-Associated
Proteins Identified Rap2B and Integrin Beta1
as Cofactors for HCV Entry
To identify members of TEM containing CD81 and CLDN1 with
a functional role in HCV entry, we analyzed the 169 identified
CD81-associated proteins (Table 1 and data not shown) for
known and predicted HRas protein interactions using ther Inc.
Figure 4. HRas Is a Host Cell Factor for HCV Entry
(A) mRNA expression of HRas, KRas and NRas compared to GAPDH after silencing of each Ras isoform with isoform-specific siRNAs.
(B) Analysis of protein expression by immunoblot with specific antibodies targeting HRas or actin after Ras silencing (siHRas.6).
(C) HCVpp entry in Huh7.5.1 cells transfected with individual siRNAs directed against HRas (si6 and si7), KRas (si1 and si8), and NRas (si5 and si11). siCTRL,
CD81, and EGFR-specific siRNAs served as internal controls. Data are expressed as percentage HCVpp entry relative to siCTRL-transfected cells (means ± SEM
from four independent experiments in triplicate, n = 12).
(D) Cell entry of pseudoparticles expressing envelope glycoproteins of influenza, measles, MLV, RD114, and VSV in Huh7.5.1 cells transfected with an individual
siRNA directed against HRas (si6). Two independent MLVpp preparations were used. siCTRL served as internal control. Data are expressed as percentage
pseudoparticle entry relative to siCTRL-transfected cells (means ± SEM from three independent experiments in triplicate, n = 9).
(E and F) Inhibition of HCV entry by erlotinib is rescued by a transdominant active HRasmutant. HCVpp entry in Huh7.5.1 cells (E) and in PHHs (F) transduced with
lentiviruses expressing a transdominant active HRas mutant (pHRas V12) and treated with erlotinib (10 mM). For HRas protein expression, see Figures S3C and
S3D. Data are expressed as percentage HCVpp entry relative to pCTRL cells (means ± SEM from four independent experiments in triplicate, n = 12).
(G) Functional role of HRas in viral cell-cell transmission. Effect of HRas silencing by siHRas.6, overexpression of HRas V12, or HRas inhibition by tipifarnib (10 mM)
on viral spread is shown. Data are expressed as percentage cell-cell transmission relative to respective controls (for RNAi, means ± SD from three independent
experiments in triplicate, n = 9; for HRas V12 and tipifarnib, means ± SD fromone representative experiment in triplicate, n = 3). SD for CTRL and tipifarnib are 0.77
and 0.68 respectively, and are thus not visible.
*p < 0.0005. See also Figure S3.
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HRas and Tetraspanin-Mediated HCV EntrySTRING database (Jensen et al., 2009; Lupberger et al., 2011).
STRING represents a metadatabase mapping all known
protein-protein interactions onto a common set of genomes
and proteins (Jensen et al., 2009). This analysis suggests
a potential network of proteins connecting CD81 and HRas
(Figure 5A) that includes known HCV entry factors CD81 and
CLDN1 and HCV host factor apolipoprotein E (apoE). Functional
analysis of members of this network using RNAi/HCVpp studies
identified Ras-related protein (Rap2B) and integrin beta1 (ITGB1)
as cofactors for HCV entry (Figure 5B). Silencing of ITGB1
and Rap2B expression was confirmed with individual siRNAsCell Ho(Figures 5C–5E). An ITGB1-specific antibody markedly and
significantly (p < 0.0001) inhibited HCV infection of Huh7.5.1 cells
and PHHs (Figures 5F and 5G), validating the role of ITGB1 for
HCV entry. These data suggest a functional network organized
by tetraspanins in the plasma membrane consisting of CD81-
CLDN1, HRas, Rap2B, and ITGB1.
HRas Is Required for Lateral Diffusion of CD81
Promoting CD81-CLDN1 Associations
Since CD81 plays a role in the lateral diffusion of HCV (Harris
et al., 2012), we studied the effect(s) of EGFR/HRas signalingst & Microbe 13, 302–313, March 13, 2013 ª2013 Elsevier Inc. 307
Table 1. Subset of CD81-Associated Proteins in HepG2-CD81
Cells Identified by SILAC Differential Proteomics, Including HRas
Interacting Partners
Protein
name ID
Sequence
(%)
MW
(kDa)
SILAC
Labeling
(Ratio H/L)
Inverted
SILAC
Labeling
[Ratio 1 / (H/L)]
CD151 P48509 13.4 28.30 15.86 64.72
EWI-2 Q969P0 47 65.03 13.93 85.67
GNAI3 P08754 22.3 40.53 13.52 41.35
CD9 P21926 7.5 25.41 13.38 231.30
CD9P-1/
EWIF
Q9P2B2 36.70 98.55 13.16 6.72
CD81 A6NMH8 30.3 29.81 12.64 111.17
ADAM10 O14672 48.3 84.14 11.45 69.25
GNAI1 P63096 20.1 40.36 11.29 14.11
RAP2B P61225 32.2 20.50 10.46 22.75
MPZ Q14902 9.2 27.95 9.05 NaN
APOE P02649 40.1 36.15 8.13 1.56
CLDN1 A5JSJ9 16.1 22.74 7.83 12.61
CD59 E9PR17 15.4 14.53 7.19 NaN
HRas P01112 20.1 21.30 5.84 103.91
RALA P11233 19.4 23.57 5.32 4.73
Integrin
alpha6
P23229 28.8 126.63 5.09 15.78
SCAMP3 O14828 9.2 38.29 4.54 NaN
Integrin
alpha1
P56199 12.4 130.85 2.98 17.16
Integrin
beta1
P05556 27.7 88.41 2.61 6.51
SR-BI Q59FM4 12.4 64.19 2.56 7.69
LMNA P02545 19.6 74.14 2.53 0.51
SOD2 P04179 13.1 24.72 NaN 2.91
LGALS1 P09382 17.0 14.72 NaN 2.56
HepG2-CD81 and HepG2 cells were differentially labeled with stable
carbon isotopes 12C or 13C (SILAC method). CD81-associated
complexes were coprecipitated with CD81, digested, and analyzed by
mass spectrometry. The protein ID, its molecular weight, the number of
the identified peptides, and total sequence coverage for each identified
protein is stated. Specificity threshold of CD81 association from each
individual identified protein was defined as a peak volume ratio H/L >2
of the differentially isotope labeled versions of each protein. The results
were validated by a second experiment with inverse isotope labeling
(inverted). The specificity threshold for the inverted SILAC labeling was
1 / (H/L) > 2. NaN, not a number. See also Figure S4.
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photobleaching (FRAP). Huh7.5.1 cells were transduced to
express AcGFP-CD81, and the basal surface was imaged by
TIRF microscopy. We observed a significant increase in CD81
diffusion coefficient (CTRL 0.09 mm2/s; tipifarnib 0.18 mm2/s,
p < 0.05) in Huh7.5.1 cells treated with the HRas inhibitor tipifar-
nib (Figure 6A). These data suggest that HRas signaling reduces
CD81 mobility by promoting an interaction with other proteins.
To investigate whether EGFR acts on CD81-CLDN1 interaction
via the putative EGFR/Shc1/HRas/BRaf pathway, we studied308 Cell Host & Microbe 13, 302–313, March 13, 2013 ª2013 Elseviewhether silencing of Shc1, HRas, or BRaf modulates CD81-
CLDN1 coreceptor interaction using a well-established fluores-
cence resonance energy transfer (FRET)-based assay (Harris
et al., 2010). Silencing of Shc1, HRas, or BRaf expression signif-
icantly (p < 0.05) reduced CD81-CLDN1 FRET in Huh7.5.1 cells
(Figures 6B–6D, black bars) while silencing had a minimal effect
on CD81-CD81 association (Figures 6B–6D, open bars). These
results demonstrate that HRas and BRaf play a role in the for-
mation and/or maintenance of the CD81-CLDN1 coreceptor
complexes. We previously reported that although EGFR stimu-
lation increased HCV entry, this process does not require
ligand-induced EGFR stimulation since the basal activity of the
receptor, even after serum starvation, is sufficient to support
HCV entry (Lupberger et al., 2011). Indeed, EGF had no signifi-
cant effect on CD81-CLDN1 FRET (data not shown), supporting
the hypothesis that the steady-state complex of CD81-CLDN1 is
dependent on low-level constitutive EGFR signaling.
These data lead us to conclude that HCV exploits the EGFR/
HRas pathway to compartmentalize host entry factors and
receptor trafficking to regulate CD81-dependent pathogen inva-
sion of the liver.
DISCUSSION
Here, we identified GTPase HRas as key signaling factor in HCV
entry. We discovered that HRas associates with CD81-CLDN1,
providing a physical link between the EGFR/Shc1/Grb2/HRas
signaling pathway and the HCV entry factor complex. Further-
more, we identified the CD81-associated proteins ITGB1 and
Rap2B as cofactors for HCV entry. We demonstrate that the
identified signaling pathway mediates CD81-CLDN1 coreceptor
associations and that HRas signaling regulates CD81 diffusion
and confinement in the plasma membrane. Since CD81 lateral
diffusion and its association with CLDN1 are essential for HCV
entry in vitro (Harris et al., 2012; Harris et al., 2010; Krieger
et al., 2010), these findings identify HRas as a trigger of HCV
entry.
HCV-CD81 engagement has been suggested to induceMAPK
(Brazzoli et al., 2008) and PI3K/AKT (Liu et al., 2012) signaling.
Moreover, EGFR function is required for HCV entry (Lupberger
et al., 2011) and HCV-CD81 engagement promotes EGFR phos-
phorylation (Diao et al., 2012). These studies suggest that HCV
may use multiple signaling pathways and mechanisms for entry;
however, the underlying molecular mechanisms and the rele-
vance of these pathways for HCV entry into human hepatocytes
or liver tissue in vivo are unknown. Since transformed hepatoma
cells such as Huh7 have deregulated signal transduction
pathways, observations might be blurred or confounded by
cell-line-specific effects. Here we combined RNAi screening,
phosphorylation arrays, and small-molecule inhibitors to study
signaling in HCV entry in primary liver cells, concluding a role
for EGF priming HRas/MAPK signaling pathway in HCV infection
of human hepatocytes and patient-derived liver tissue (Figures 1
and S1).
Interestingly, although in our hands silencing of PI3K regula-
tory subunit 1 (PI3KR1) expression reduced HCVpp entry (data
not shown) as previously shown (Liu et al., 2012), we failed to
validate its functional relevance for HCV entry using two different
small-molecule PI3K inhibitors (Figures 3G and S2A–S2C).r Inc.
Figure 5. Functional Analysis of HRas-CD81-Associated Proteins Identifies Integrin Beta1 andRap2B as Previously UndiscoveredHCV Entry
Factors
(A) Subset of TEM protein association network of the 169 proteins associating with HRas and CD81 identified by STRING analysis (Jensen et al., 2009). Lines
connecting proteins show direct (physical) and indirect (functional) associations derived from numerous sources, including experimental repositories (red lines),
computational prediction methods (blue lines), databases (yellow lines), and public text collections (green lines).
(B) Functional analysis of protein association network via RNAi. HCVpp entry in Huh7.5.1 cells transfected with pooled siRNA directed against identifiedmembers
of CD81-associated protein network containing HRas. siCTRL and CD81-specific siRNA served as internal controls. Data are expressed as percentage HCVpp
entry relative to siCTRL-transfected cells (means ± SD from one representative experiment, n = 3).
(C) Analysis of protein expression in lysates of Huh7.5.1 with silenced Rap2B expression by immunoblot with specific antibodies targeting Rap2B or actin (Rab2B
pool siRNA).
(D and E) mRNA expression of Rap2B (D) and integrin beta1 (ITGB1) (E) compared to GAPDH or HCVpp entry after silencing of each protein with individual
siRNAs. Huh7.5.1 cells were silenced with siRAP2B.3 or siRAP2B.4 and siITGB1.2 or siITGB1.4 for 72 hr prior to mRNA expression measurement or to HCVpp
infection of Huh7.5.1 cells. siCTRL and CD81-specific siRNA served as internal controls. Data are expressed as mRNA expression of Rap2B or ITGB1 compared
to GAPDH (means ± SD from one representative experiment in triplicate, n = 3) or percentage HCVpp entry relative to siCTRL-transfected cells (means ± SEM
from three independent experiments in triplicate, n = 9).
(F and G) Effect of a neutralizing ITGB1-specific antibody on HCV entry and infection. Huh7.5.1 cells (F) or PHHs (G) were treated with 25 mg/ml antibodies 1 hr
prior and during infection with HCVpp or HCVcc. Irrelevant rabbit and mouse IgGs and a CD81-specific antibody were used as controls. Data are expressed as
percentage HCVpp entry or HCVcc infection relative to cells treated with irrelevant IgG (means ± SEM from four experiments in triplicate, n = 12).
*p < 0.0001.
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had no significant impact on HCVpp entry (Figure 2), and EGFR
signaling through AKT was limited or absent in PHHs or liver
tissue in vivo (Figures 1 and S1). Thus, our data suggest that
HRas and the upstream MAPK pathway are key signal trans-
ducers for EGFR-mediated HCV entry into PHHs and the human
liver in vivo and that signal transduction through the PI3K/AKT
pathway most likely plays only a minor role.
Our functional analyses suggest that HRas acts as amolecular
switch promoting RTK-mediated HCV entry. Inhibition/rescueCell Hoexperiments highlight that EGFR-mediated HCV entry is depen-
dent on HRas function. Our observation that HRas associates
with tetraspanin CD81 supports our biochemical data showing
that HRas links RTK signaling to CD81 and promotes CD81-
CLDN1 association. This is in line with the recent finding that
CD81 internalization via a clathrin- and dynamin-dependent
process is independent of the CD81 cytoplasmic domain, sug-
gesting a role for associated partner proteins in regulating
CD81 trafficking (Farquhar et al., 2012). Moreover, it has been
reported that CD81 engagement activates Rho GTPase familyst & Microbe 13, 302–313, March 13, 2013 ª2013 Elsevier Inc. 309
Figure 6. HRas Is Required for Lateral Diffusion of CD81 Promoting CD81-CLDN1 Associations
(A) AcGFP-CD81 diffusion coefficient in Huh7.5.1 cells after 4 hr treatment with DMSO or 10 mM tipifarnib. The median CD81 diffusion coefficient (DMSO,
0.09 mm2/s; tipifarnib, 0.18 mm2/s) is shown, with each point representing a bleached region of interest and the black line represents the median value.
(B–D) FRET of CD81-CD81 (open bars) and CD81-CLDN1 (black bars) coreceptor associations in Huh7.5.1 cells incubated with siRNA specific for Shc1 (B), HRas
(C) or BRaf (D) (means ± SEM from ten independent experiments, n = 10).
*p < 0.05.
Cell Host & Microbe
HRas and Tetraspanin-Mediated HCV Entrymembers leading to actin-dependent relocation of HCV E2-
CD81 and activation of Raf/MAPK signaling (Brazzoli et al.,
2008). Membrane microdomains, such as TEMs or lipid rafts,
play a role in a variety of physiological and pathological
processes, for instance as signaling platform (Le Naour et al.,
2006). TEMs and lipid rafts differ in their solubility in Triton X-
100, as well as in their protein composition, and thus are distinct
membrane microdomains (Le Naour et al., 2006). GDP-bound
inactive HRas is associated to lipid rafts, whereas GTP-bound
active HRas is segregated from lipid rafts to bulk plasma
membrane microdomains where it activates signal transduction
including the Raf/MAPK pathway (Tian et al., 2007). Thus, it is
likely that EGFR-induced signals activate HRas function and
that GTP-bound activated HRas leads to rearrangement of
tetraspanins, resulting in formation of the essential CD81-
CLDN1 entry receptor complex.
Our functional analysis of HRas-CD81-associated proteins
demonstrates for the first time a functional role of the GTPase
Rap2B and ITGB1 as cofactors for HCV entry. Like HRas,
Rap GTPases are known regulators of integrin function. Rap
increases integrin avidity by promoting integrin clustering
(Kinbara et al., 2003) that may have an important impact on the
CD81 TEM formation. ITGB1 is a major TEM component. Integ-
rins are heterodimeric transmembrane proteins composed of
an alpha and a beta subunit that couple the extracellular matrix
to the F-actin cytoskeleton and signal in a bidirectional manner
(Wickstro¨m and Fa¨ssler, 2011). Conformational changes of
integrins elicit signaling events that promote cytoskeletal
rearrangement and internalization of many viruses (Stewart and
Nemerow, 2007). EGFR can be activated in an ITGB1-dependent
manner, and ITGB1 controls EGFR signaling (Morello et al.,
2011; Moro et al., 1998), suggesting a crosstalk between
ITGB1 and EGFR in HCV entry. Collectively, these findings
suggest that HRas acts together with Rap2B and ITGB1 to
form a functional complex that may regulate host cell entry
receptor mobility, as well as plasma membrane and cytoskel-
eton organization.310 Cell Host & Microbe 13, 302–313, March 13, 2013 ª2013 ElsevieIndeed, the HRas inhibitor tipifarnib promotes CD81 lateral
diffusion speed, suggesting an inhibitory role for HRas to regu-
late CD81 diffusion coefficient at the plasma membrane. We
previously reported that hepatoma polarization limits CD81
and HCVpp diffusion coefficient (Harris et al., 2012), concluding
that CD81 lateral movement plays an essential role in HCV
glycoprotein-dependent particle dynamics that are essential
for efficient particle entry.
Our results emphasize that TEMs are active and dynamic
areas of the membrane and uncover an important role of
GTPases as molecular switches to provide a functional link
between TEM-associated tetraspanins and the cytoskeleton,
allowing efficient coreceptor complex formation and cellular
entry of viruses. Indeed, tetraspanins have been associated
with the initiation of infection by various pathogens. Moreover,
a recent functional siRNA screen has suggested a potential
role for CD81 and HRas for influenza virus entry (Karlas et al.,
2010), although their exact function in this process was not
investigated. Here, we demonstrate that silencing HRas inhibits
the entry of pseudoparticles expressing glycoproteins of influ-
enza A andmeasles virus but not MLV or VSV. Collectively, these
findings highlight a functional relevance for HRas and its role in
plasma membrane compartmentalization and receptor traf-
ficking for entry of viruses of other families. Furthermore, our
results identify a mechanism to regulate CD81-dependent
pathogen invasion of the liver that is HRas dependent.
Finally, our results might have therapeutic implications for the
treatment of viral infections. Pharmacological interference with
BRaf and HRas might provide an approach for fighting a broad
range of viral infections including hepatitis C, influenza, and
measles. Indeed, host-targeting agents are an emerging strategy
to overcome antimicrobial resistance, a major limitation of
direct-acting antivirals or antibiotics (Nathan, 2012). The recent
development of safe and efficient clinically licensed small-mole-
cule inhibitors of GTPase and BRaf (Downward, 2003; Maurer
et al., 2011; Vanneman and Dranoff, 2012) provides a unique
opportunity to develop host-targeting antiviral strategies. Inr Inc.
Cell Host & Microbe
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understanding of viral entry and pathogenesis, but also for the
development of preventive and therapeutic antiviral strategies.
EXPERIMENTAL PROCEDURES
Cell Lines and Primary Human Hepatocytes
The sources and culture conditions for 293T, Huh7, Huh7.5.1, HepG2, and
HepG2-CD81 cells have been described (Lupberger et al., 2011; Mee et al.,
2009). PHHs were isolated and cultured as described (Krieger et al., 2010;
Lupberger et al., 2011). Polarization of HepG2-CD81 was induced as
described (Mee et al., 2009).
Patient-Derived Liver Biopsies
Liver biopsy tissues were analyzed as described (Dill et al., 2012). Liver tissue
was lysed and subjected to immunoblot and phosphorylation array analysis
(described below). For ex vivo stimulation, liver tissue was incubated for
15min with 1 mg/ml EGF. The protocol was approved by the Ethics Committee
of the University Hospital of Basel, Switzerland. Written informed consent
was obtained from all patients.
Analysis of Cell Signaling with Phosphorylation Arrays
Lysates of cells and liver biopsies were subjected to the proteome Profiler
Array human phosphokinase array and human phospho-RTK array (R&D
Systems) according to the manufacturer’s protocol.
Dynamic Phosphoflow Analyses
Phosphorylated forms of ERK1/ERK2 and AKT were quantified with phospho-
specific antibodies in the presence of the phosphatase inhibitor pervanadate,
EGF, and kinase inhibitors as described (Firaguay and Nune`s, 2009). Cells
were fixed, permeabilized, and incubated successively with rabbit antibodies
directed against pAKT or pERK1/pERK2, biotinylated anti-rabbit antibodies,
and a streptavidin-phycoerythrin solution (Beckman Coulter, Paris, France).
Infection of Cells with Viral Pseudoparticles and Cell-Culture-
Derived HCV
Lentiviral pseudoparticles expressing envelope glycoproteins from HCV
(strains HCV-J and P01VL), VSV, MLV, measles, RD114, avian fowl plague
influenza A (H7N1), and HCVcc (strain Luc-Jc1) were generated as described
(Lupberger et al., 2011). Infection of Huh7.5.1, HepG2-CD81 cells, and PHHs
with pseudoparticles and HCVcc were performed as described (Krieger et al.,
2010; Lupberger et al., 2011). Unless otherwise stated, pseudoparticle entry
and HCVcc infection were assessed by measurement of luciferase activity
72 hr after infection as described (Krieger et al., 2010; Lupberger et al.,
2011). HCV cell-cell transmission was assayed as described (Lupberger
et al., 2011) and is detailed in the Supplemental Experimental Procedures.
Functional RNAi HCV Entry Screens
siRNA screens targeting known EGFR binding partners and CD81-associated
proteins were applied in Huh7.5.1 cells as described (Lupberger et al., 2011)
with ON-TARGETplus smart pools (pools of four individual siRNAs; Dharma-
con). For each target, 5.25 pmol siRNA was reverse transfected in 5,000
Huh7.5.1 cells per well of a 96-well microplate with INTERFERin (Polyplus).
Rescue of EGFR Inhibition with a HRas Transcomplementation
Assay
Huh7.5.1 cells (0.66 3 104) or PHHs were seeded as described (Lupberger
et al., 2011) 1 day prior to transduction with lentiviruses expressing the trans-
dominant active HRas V12 mutant or control (Beause´jour et al., 2003).
Seventy-two hours later, cells were infected with HCVpp in the presence of
10 mM erlotinib or DMSO control.
Proteomic Analyses of Tetraspanin Complexes and Microdomains
SILAC was performed as described (Ong et al., 2002). HepG2-CD81 cells and
control HepG2 were incubated with either light or heavy isotope labeled
amino acids and then lysed with brij97. The two lysates were pooled, and
CD81-associated proteins were coimmunoprecipitated as described (Andre´Cell Hoet al., 2006). The proteins were separated by SDS-PAGE and identified by
liquid chromatography-mass spectrometry. A peak volume ratio heavy/light
>2 was defined as threshold for potential CD81-associated proteins. More
details are given in the Supplemental Experimental Procedures.
Imaging Studies
FRAP was performed as described (Harris et al., 2012). Huh7.5.1 cells were
transduced with GFP-labeled CD81 (AcGFP-CD81), and CD81 motility was
assessed at the membrane of live cells with TIRF microscopy after photo-
bleaching. FRET analyses of homotypic and heterotypic interactions of
CD81 and CLDN1 were analyzed in Huh7.5.1 cells as described (Harris
et al., 2010). The data from ten cells were normalized, and the localized ex-
pression was calculated. Confocal microscopy and staining was performed
as described (Chambrion and Le Naour, 2010). Colocalization was calculated
according to Pearson and Manders (Bolte and Cordelie`res, 2006; Manders
et al., 1992). More details are given in the Supplemental Experimental
Procedures.
Statistical Analysis
All experiments were performed at least three times in triplicate in an inde-
pendent manner, and results were analyzed with the nonparametric Mann-
Whitney test if not indicated otherwise. An F test was performed for analysis
of variance (one-way ANOVA) of colocalization studies to compare means of
two groups (n = 3) of Pearson’s correlation coefficient (Rr) or ICQ. Significant
p values are indicated by an asterisk in the individual figure legends.
Additional information on experimental procedures is provided in the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chom.2013.02.006.
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